Active	Status	Sponsor type	Region	Phase	Filter
10 Active 1 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bachier, Carlos
NCT03436862: Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk	Completed	2	37	US	Nivolumab, Opdivo	SCRI Development Innovations, LLC, Bristol-Myers Squibb	Hodgkin Lymphoma	05/22	04/23
Cruz, Jose De La
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Initiation of new trial in Ph+ ALL Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone	Takeda	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	08/22	07/27
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease	Recruiting	2/3	1912	Canada, US	Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month	NRG Oncology, Natera, Inc., National Cancer Institute (NCI)	Stage III Colon Cancer	03/29	03/30